CH
ASBPW

CVI Holdings’s Aspire Biopharma Warrant ASBPW Stock Holding History

CVI Holdings’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-24,600
Closed -$1.97K – 462
2022
Q4 		$1.97K Sell
24,600
-400
-2% -$27 ﹤0.01% 515
2022
Q3 		$3K Hold
25,000
– – ﹤0.01% 763
2022
Q2 		$3K Buy
+25,000
New +$5.44K ﹤0.01% 884

Other funds holding ASBPW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

CVI Holdings's ASBPW Position: Q1 2023 in Review

CVI Holdings sold out of Aspire Biopharma Warrant (ASBPW) in Q1 2023, closing a stake of 24,600 shares — an estimated $1.97K sold.

CVI Holdings first reported a position in ASBPW in Q2 2022 and held it in 3 quarters. The position peaked at $3K in Q3 2022. 35 funds tracked by Wall St. Rank hold ASBPW as of Q1 2023.

  • CVI Holdings reported no remaining Aspire Biopharma Warrant position as of Q1 2023 after selling out during the quarter.
  • CVI Holdings sold 24,600 Aspire Biopharma Warrant shares in Q1 2023, an estimated $1.97K.
  • CVI Holdings first reported a position in Aspire Biopharma Warrant in Q2 2022 and held it in 3 quarters.
  • CVI Holdings's Aspire Biopharma Warrant position peaked at $3K in Q3 2022.
  • 35 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q1 2023.

Based on CVI Holdings's 13F filing for Q1 2023, filed 16 May 2023.